Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Tumor Progression02:07

Tumor Progression

6.3K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K
Disorders of Leukocytes01:27

Disorders of Leukocytes

946
Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
946

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Molecular measurable residual disease by immunoglobulin gene rearrangements on circulating tumor DNA predicts outcome in diffuse large B-cell lymphoma.

Haematologica·2024
Same author

Immunoglobulin light chain mutational status refines IGHV prognostic value in identifying chronic lymphocytic leukemia patients with early treatment requirement.

Leukemia·2024
Same author

Efficacy and safety of bendamustine, rituximab and bortezomib treatment in relapsed/refractory Waldenstrom Macroglobulinaemia: results of phase 2 single-arm FIL-BRB trial.

British journal of haematology·2024
Same author

CAT rs1001179 Single Nucleotide Polymorphism Identifies an Aggressive Clinical Behavior in Chronic Lymphocytic Leukemia.

Hematological oncology·2024
Same author

High Mitophagy and Low Glycolysis Predict Better Clinical Outcomes in Acute Myeloid Leukemias.

International journal of molecular sciences·2024
Same author

A Rare Case of Life-Threatening Jaundice Caused by Epstein-Barr Virus Infection and Secondary Cold Agglutinin Syndrome Successfully Treated with Rituximab.

International medical case reports journal·2024

相关实验视频

Updated: Jun 29, 2025

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

21.1K

慢性淋巴细胞白血病的预后.

Riccardo Moia1, Gianluca Gaidano1

  • 1Division of Hematology, Department of Translational Medicine, Università del Piemonte Orientale, Novara, Italy.

Seminars in hematology
|March 24, 2024
PubMed
概括

预后标志物对于慢性淋巴细胞白血病 (CLL) 患者分层至关重要. 识别高风险患者指导个性化治疗策略,以在这种异质白血病中获得更好的结果.

科学领域:

  • 血液学 血液学 血液学
  • 在瘤学瘤学.
  • 分子生物学分子生物学

背景情况:

  • 慢性淋巴细胞白血病 (CLL) 是一种异质的恶性瘤,临床过程可变.
  • 需要有效的预后标志物来指导治疗决策并识别高风险患者.

研究的目的:

  • 审查CLL的预后标志物,以预测治疗需求,进展和转变.
  • 突出在特定患者子组中需要精细化生物标志物.

主要方法:

  • 审查关于CLL预后标志物的现有文献.
  • 分析临床试验数据和生物标志物研究.

主要成果:

  • TP53中断可以识别持续使用BTK抑制剂的高风险患者.
  • 在固定持续时间的venetoclax-obinutuzumab和BTK抑制剂之间,IGHV突变状态和TP53状态指导选择.
  • 克隆与CLL的关系是里希特综合征最强的预后标志物.

结论:

  • 预后标志物对于定制CLL治疗至关重要,包括BTK抑制剂和venetoclax-obinutuzumab.
  • 需要进一步的研究来确定生物标志物,以优化IGHV未变异的CLL治疗持续时间.
关键词:
在 CLL CLL 中.精准医学是一门精准的医学.预测者 预测者预测者 预测者

更多相关视频

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
11:29

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

11.0K
From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
10:18

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

Published on: October 19, 2014

13.7K

相关实验视频

Last Updated: Jun 29, 2025

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

21.1K
HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
11:29

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

11.0K
From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
10:18

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

Published on: October 19, 2014

13.7K
  • 里希特综合征仍然是一个未得到满足的临床需求,需要新的治疗策略.